TIAA CREF Investment Management’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

TIAA CREF Investment Management’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-157,589	Closed	-$230K	–	3293
2016 Q1	$230K	Hold	157,589	–	–	﹤0.01%	2962
2015 Q4	$504K	Hold	157,589	–	–	﹤0.01%	2891
2015 Q3	$985K	Hold	157,589	–	–	﹤0.01%	2582
2015 Q2	$1.56M	Buy	157,589 +22,721	+17%	+$199K	﹤0.01%	2456
2015 Q1	$994K	Buy	134,868 +10,463	+8%	+$70.4K	﹤0.01%	2625
2014 Q4	$666K	Sell	124,405 -76,227	-38%	-$390K	﹤0.01%	2862
2014 Q3	$1.01M	Buy	200,632 +16,500	+9%	+$101K	﹤0.01%	2620
2014 Q2	$1.24M	Buy	+184,132	New	+$1.17M	﹤0.01%	2587

Other funds holding NWBO

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

TIAA CREF Investment Management's NWBO Position: Q2 2016 in Review

TIAA CREF Investment Management sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q2 2016, closing a stake of 157,589 shares — an estimated $230K sold.

TIAA CREF Investment Management first reported a position in NWBO in Q2 2014 and held it in 8 quarters. The position peaked at $1.56M in Q2 2015. 64 funds tracked by Wall St. Rank hold NWBO as of Q2 2016.

TIAA CREF Investment Management reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q2 2016 after selling out during the quarter.
TIAA CREF Investment Management sold 157,589 Northwest Biotherapeutics, Inc. Common stock shares in Q2 2016, an estimated $230K.
TIAA CREF Investment Management first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q2 2014 and held it in 8 quarters.
TIAA CREF Investment Management's Northwest Biotherapeutics, Inc. Common stock position peaked at $1.56M in Q2 2015.
64 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q2 2016.

Based on TIAA CREF Investment Management's 13F filing for Q2 2016, filed 11 Aug 2016.